2019, Number 1
PDF size: 347.60 Kb.
ABSTRACTOne of every ten non-Hodgkin lymphomas (NHL) are of T lineage, there are limitations to diagnose and treat this group of patients. It is necessary to have documents about their clinical characteristics, location of these varieties, classification systems and ideal treatment. The present review make a concentration of the aforementioned, with the purpose of consensus epidemiology, morphological characteristics, studies, evaluation techniques and the types of treatment to be performed, in order to offer to this group of patients an evaluation and more systematic management. This document include LNH of the varieties: T/NK nasal, mycosis fungoides, peripheral T and lymphoblastic. As the number of patients and studies with more limitations is smaller than offering solid evidence in this field, due to the greater heterogeneity of the T line NHL, it is intended to concentrate the different positions in different groups, which allows us to homogenize the approach diagnosis and therapy that improves the results so far in response rates and survival. Finally, by integrating into our environment, diagnostic tools, treatment and evaluation improve the results in this population.
Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29(18):2598-607.
Szczepański T, Pongers-Willemse MJ, Langerak AW, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999;93(12):4079-4085.
Bernard A, Boumsell L, Reinherz EL, et al. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 1981;57(6):1105-1110.